Fig. 8: Loss of NR2F6 protects against B16-F10-B2m^−/− lung metastasis formation.

A Gross examination and quantification of representative metastatic tumor foci in the lung at day 16 after B16-F10-B2m^−/− tumor inoculation of either Nr2f6^+/+ mice or Nr2f6^−/− mice, with or without IL-15C treatment (i.v.-injected). B Representative dot-plots (tumor) and quantification of splenic, blood, and lung metastasis-derived NK cell frequencies (CD45⁺CD3^-CD19^-NK1.1⁺NKp46⁺) in wild-type (Nr2f6^+/+) or Nr2f6-deficient (Nr2f6^−/−) mice on day 16 after B16-F10-B2m^−/− tumor injection. C Quantification of NKp46 expression (MFI) in splenic, blood, and lung metastasis-derived NK cells (CD45⁺CD3^-CD19^-NK1.1⁺NKp46⁺) in wild-type (Nr2f6^+/+) or Nr2f6-deficient (Nr2f6^−/−) mice on day 16 after B16-F10-B2m^−/− tumor injection. D Quantification of the frequency of terminally matured (CD27^-CD11b⁺KLRG1⁺) NK cells (CD45⁺CD3^-CD19^-NK1.1⁺NKp46⁺) in the spleen, the blood and lung metastasis in wild-type (Nr2f6^+/+) or Nr2f6-deficient (Nr2f6^−/−) mice. A Representative data are shown as pooled experiments n = 16 (Nr2f6^+/+) n = 17 (Nr2f6^−/−) from five experiments. IL-15C treated Nr2f6^−/− mice are shown as pooled experiments n = 10 from two experiments. B Representative data are shown as pooled experiments from three independent experiments n = 7–11. D Representative data are shown as pooled experiments from two independent experiments n = 5–7. Each dot represents the data of an individual mouse. Results are shown as mean ± SD. The normality of data was evaluated by the Shapiro–Wilk test. An asterisk indicates statistically significant differences between genotypes calculated using Student’s t-test or Mann-Whitney U test. A p value < 0.05 was considered statistically significant. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.